CA1267084A - Method for determining mimotopes - Google Patents
Method for determining mimotopesInfo
- Publication number
- CA1267084A CA1267084A CA000507185A CA507185A CA1267084A CA 1267084 A CA1267084 A CA 1267084A CA 000507185 A CA000507185 A CA 000507185A CA 507185 A CA507185 A CA 507185A CA 1267084 A CA1267084 A CA 1267084A
- Authority
- CA
- Canada
- Prior art keywords
- monomers
- catamers
- catamer
- receptor
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
Abstract
A B S T R A C T
A method of detecting or determining the sequence of monomers which is a topographical equivalent of the ligand which is complementary to a particular receptor of interest, the method comprises the steps of:-1. synthesizing a plurality of catamers, each said catamer being of the general formula:
wherein D1 represents a designated monomer selected from a first set of monomers, and D2 represents a designated monomer selected from a second set of monomers which may be the same as or different to said first set of monomers;
said plurality of catamers comprising catamers in which each designated monomer is systematically varied to contain members from the respective set of monomers;
2. contacting each catamer with the receptor of interest, and, 3. detecting or determining the presence or absence of binding between each catamer and said receptor.
The method may also include the synthesis of further pluralities of catamers, including catamers containing spacer molecules, to build up a sequence of monomers which is the mimotope of the ligand.
A method of detecting or determining the sequence of monomers which is a topographical equivalent of the ligand which is complementary to a particular receptor of interest, the method comprises the steps of:-1. synthesizing a plurality of catamers, each said catamer being of the general formula:
wherein D1 represents a designated monomer selected from a first set of monomers, and D2 represents a designated monomer selected from a second set of monomers which may be the same as or different to said first set of monomers;
said plurality of catamers comprising catamers in which each designated monomer is systematically varied to contain members from the respective set of monomers;
2. contacting each catamer with the receptor of interest, and, 3. detecting or determining the presence or absence of binding between each catamer and said receptor.
The method may also include the synthesis of further pluralities of catamers, including catamers containing spacer molecules, to build up a sequence of monomers which is the mimotope of the ligand.
Description
~;26~
"IMPROVED MET~TOD FOR DETERMINING MIMOTOPES"
This invention relates to a method of detecting or determining a sequence of monomer molecules which corresponds to the ligand molecule for a particular receptor. The sequence of monomer molecules so determined is the mimotope (defined below) of the particular ligand. The mimotope which is determined by this method may not have any obvious or direct relationship to the natural ligand molecule, but will share with it the ability to react with the receptor, and indeed, the mimotope so determined may be modified to incorporate specific or additional properties in the reaction with the receptor. Such a mimotope could then be used to replace the natural ligand in the treatment or prevention of particular disease or it may be used to mediate a particular biological effect.
As used throughout this specification, the terms listed below have the following meanings:-receptor: a molecule or molecular complex which will combine specifically with its particular ]igand molecule. It is those receptors which on binding with their particular ligand(s) mediate a biological function that are of most interest. Examples of receptors include, but 3~
8~
are not restric-ted to, the common class of receptors associated with the surface membrane of cells and include, for instance, the immunologically important receptors of B-cells, T-cells, macrophages and the like.
Another example is receptors -Eor acetyl choline on nerve cells which cause a nerve pulse to be transmitted down the length of the neuron when the receptor molecule reacts with its ligand, acetyl choline.
epitope: the specific surface of an antigen molecule which is delineated by the area of interaction with the sub-class of receptors known as antibodies.
catamer: a polymer molecule which is a precisely defined linear sequence formed by the condensation of small moleculesO Note that this term includes molecules in which different types of condensation reactions are used to ~oin the small molecules. A number prefixed to the word "catamer" implies that the catamer is formed by the condensation of the indicated number of small molecules, for example, 8-catamer means that the catamer is made up from eight small molecules. Examples of catamers include any given peptide and any given oligo-saccharide.
monomer: a member of the set of small molecules which can be condensed together to form a catamer. The set of monomers includes but is not restricted to, for example, the set of ~7~8~
common L-amino acids, the set of D-amino acids, the set of synthetic amino acids, the set of nucleotides, and the set of pentoses and hexoses.
peptide: a catamer in which the small Molecules are alpha-amino acids and which are ioined together through a peptide bond~ In the context of this specification it should be appreciated that the amino acids may be the I.-optical isomer or the D optical isomer.
mimotope: a catamer which in at least one of its conformations has a surface region with the equivalent molecular topology to the binding - surface of the ligand molecule of which it is the mimic. Tn the context of immunological receptors, the mimotope mimics the epitope of the antigen.
complementary: refers to the matching together of the reacting surfaces of an ligand molecule and its receptor. Thus, the receptor and its ligand can be described as complementary, and furthermore, the contact surface characteristics are complementary to each other.
paratope: the combining site of an antibody which is complementary to a particular epitope.
ligand molecule: is the molecule which binds to a particular receptor and when bound to it 126~;84 mediates the bio]ogical function associated with that particular receptor.
Examples of receptors which can be investigated by this method include, but are not restricted to:-hormone receptors: for instance the receptors forinsulin and Growth Hormone; determination of the mimotopes of the ligands binding to these receptors may lead to the development of an oral replacement of the daily in~ections which d:iabetics must take to relieve the svmptoms of diabetes, and in the other case, a replacement for the scarce human Growth Hormone which can only be obtained from cadavers or by recombinant DNA technology. Other examples are the vasoconstrictive hormone receptors;
determination of the mimotope of the ligand binding to these receptors may lead to the development of drugs to control blood pressure.
opiate receptors: determination of mimotopes of the ligands hinding to the opiate-receptors in the brain may lead to the development of less-addictive replacements for morphine and related drugs.
microorganism receptors: determination of mimotopes of the ligands binding to a receptor such as specific transport proteins or enzymes essential to survival to microorganisms, may lead to a new class of antibiotics. Of particular value would be antibiotics against ~2~7~
protozoa and those bacteria resistant to the antibiotics in current use.
enzymes: for instance, the enzymes responsible for cleaving neural transmitters; determination of mimotopes able to modulate the action of the en~ymes which cleave the different neural transmitters may lead to the development of drugs which can be used in the treatment of disorders of neural transmission; and, antibodies: for instance the ligand-binding site on the antibody molecule which combines with the epitope of an antigen of interest;
determination of a mimotope for the epitope may lead to the development of vaccines of which the immunogen is based on one or more mimotopes or diagnostic agents or compounds useful in the therapeutic treatment of autoimmune diseases.
Examples of ligands which can be investigated by this method include, but are not restricted to:~
toxins and venoms: for instance, the combining site of the toxin molecule which reacts with a particular receptor in the body to give the particular symptom(s) of intoxication;
determination of mimotopes to the combining site of the ligand may lead to the development of drugs which can be used to treat envenomation by snakes and other poisonous animals without the side effects of heterologous antivenenes.
virus and other microorganism capsid molecules:
1.2~7~
for instance, the combining site on the virus coat molecule which reacts with a particular receptor on the cell membrane in the body and which allows the virus to invade and thus infect the particular cell; determination of mimotopes to this combining site may lead to the development of drugs which specifically prevent intracellular invasion by the virus and thus prevent their replication.
It is a primary obiect of this invention to detect or determine one or more short sequences of monomers (catamers) which selectively combine with a particular receptor so as to mediate its biological function. These catamers are the mimotopes of the ligand. This information is invaluable -for the design of very specific diagnostic and therapeutic agents.
The most usual group of small molecules which may be condensed together to form a catamer is the group of alpha-amino acids. However, other molecules which are consistent with a different chosen chemistry may also be used; for example, catamers formed from the specified sequential condensation of nucleotides or saccharides. Another group of small molecules would be the non-genetically coded amino acids such as beta-amino acids, which may be used to advantage to add an additional bond at specified positions within the catamer.
The method of the present invention is based on the realisation that a given receptor will specifically react with a catamer which is the mimotope for the liga~d to which the receptor is directed. It 8 L~
further relies on modern techniques of immunology to detect reaction between a receptor and its ligand when both are present.
In Canadian Patent Application 487,281 it is proposed to delineate mimotopes based on an overall length of about ~
monomers. It is now clear that the preferred method for the delineation of mimotopes is -from shorter catamers (2 or 3 monomers long) made up from all combinations of monomers from either:-(i) two sets oE monomers, which may be identical, or (ii) three sets of monomers, of which the centre monomer of the catamer is selected from a set of special chosen monomers which confer known spatial relationships on the other two monomers, the remaining monomers of the catamer coming from two sets of monomers which may be identical.
Furthermore, it has now been shown that the sensitivity of detection of binding to receptors is reduced in some instances where the monomers are synthesized in catamer preparations as disclosed in Canadian Patent Application ~o. 487,281.
We have now demonstrated that reaction is readily detected between a receptor and short mimotopes. These shortmimotopes when condensed together then bind to the receptor with either a greater affinity or with greater specificity for that receptor. This reaction can be detected even when the short mimotope presented to the receptor is as small as two monomer molecules long. By determining the op-timum short mimotope at each stage and then testing further variants, the final structure of a strongly-binding mimotope can be determined.
~;~67~
~ ccording to the present invention there is provided a method of detecting or determining the sequence of monomers which is a topographical equivalent of the ligancl which is complementary to the particular receptor of interest and prior knowledge is irrelevant about the identity, structure and sequence of the receptor or its ligand. The method comprises the steps of:-0 1. synthesizing a plurality oF catamers, each saiclcatamer being of the general formula:
D -Dl wherein Dl represents a designated monomer selected from a first set of monomers, and D~ represents a designated monomer selected from a second set of monomers which may be the same as or different to said first set of monomers; said plurality of catamers comprising catamers in which each designated monomer is systematically varied to contain members from the respective set of monomers;
"IMPROVED MET~TOD FOR DETERMINING MIMOTOPES"
This invention relates to a method of detecting or determining a sequence of monomer molecules which corresponds to the ligand molecule for a particular receptor. The sequence of monomer molecules so determined is the mimotope (defined below) of the particular ligand. The mimotope which is determined by this method may not have any obvious or direct relationship to the natural ligand molecule, but will share with it the ability to react with the receptor, and indeed, the mimotope so determined may be modified to incorporate specific or additional properties in the reaction with the receptor. Such a mimotope could then be used to replace the natural ligand in the treatment or prevention of particular disease or it may be used to mediate a particular biological effect.
As used throughout this specification, the terms listed below have the following meanings:-receptor: a molecule or molecular complex which will combine specifically with its particular ]igand molecule. It is those receptors which on binding with their particular ligand(s) mediate a biological function that are of most interest. Examples of receptors include, but 3~
8~
are not restric-ted to, the common class of receptors associated with the surface membrane of cells and include, for instance, the immunologically important receptors of B-cells, T-cells, macrophages and the like.
Another example is receptors -Eor acetyl choline on nerve cells which cause a nerve pulse to be transmitted down the length of the neuron when the receptor molecule reacts with its ligand, acetyl choline.
epitope: the specific surface of an antigen molecule which is delineated by the area of interaction with the sub-class of receptors known as antibodies.
catamer: a polymer molecule which is a precisely defined linear sequence formed by the condensation of small moleculesO Note that this term includes molecules in which different types of condensation reactions are used to ~oin the small molecules. A number prefixed to the word "catamer" implies that the catamer is formed by the condensation of the indicated number of small molecules, for example, 8-catamer means that the catamer is made up from eight small molecules. Examples of catamers include any given peptide and any given oligo-saccharide.
monomer: a member of the set of small molecules which can be condensed together to form a catamer. The set of monomers includes but is not restricted to, for example, the set of ~7~8~
common L-amino acids, the set of D-amino acids, the set of synthetic amino acids, the set of nucleotides, and the set of pentoses and hexoses.
peptide: a catamer in which the small Molecules are alpha-amino acids and which are ioined together through a peptide bond~ In the context of this specification it should be appreciated that the amino acids may be the I.-optical isomer or the D optical isomer.
mimotope: a catamer which in at least one of its conformations has a surface region with the equivalent molecular topology to the binding - surface of the ligand molecule of which it is the mimic. Tn the context of immunological receptors, the mimotope mimics the epitope of the antigen.
complementary: refers to the matching together of the reacting surfaces of an ligand molecule and its receptor. Thus, the receptor and its ligand can be described as complementary, and furthermore, the contact surface characteristics are complementary to each other.
paratope: the combining site of an antibody which is complementary to a particular epitope.
ligand molecule: is the molecule which binds to a particular receptor and when bound to it 126~;84 mediates the bio]ogical function associated with that particular receptor.
Examples of receptors which can be investigated by this method include, but are not restricted to:-hormone receptors: for instance the receptors forinsulin and Growth Hormone; determination of the mimotopes of the ligands binding to these receptors may lead to the development of an oral replacement of the daily in~ections which d:iabetics must take to relieve the svmptoms of diabetes, and in the other case, a replacement for the scarce human Growth Hormone which can only be obtained from cadavers or by recombinant DNA technology. Other examples are the vasoconstrictive hormone receptors;
determination of the mimotope of the ligand binding to these receptors may lead to the development of drugs to control blood pressure.
opiate receptors: determination of mimotopes of the ligands hinding to the opiate-receptors in the brain may lead to the development of less-addictive replacements for morphine and related drugs.
microorganism receptors: determination of mimotopes of the ligands binding to a receptor such as specific transport proteins or enzymes essential to survival to microorganisms, may lead to a new class of antibiotics. Of particular value would be antibiotics against ~2~7~
protozoa and those bacteria resistant to the antibiotics in current use.
enzymes: for instance, the enzymes responsible for cleaving neural transmitters; determination of mimotopes able to modulate the action of the en~ymes which cleave the different neural transmitters may lead to the development of drugs which can be used in the treatment of disorders of neural transmission; and, antibodies: for instance the ligand-binding site on the antibody molecule which combines with the epitope of an antigen of interest;
determination of a mimotope for the epitope may lead to the development of vaccines of which the immunogen is based on one or more mimotopes or diagnostic agents or compounds useful in the therapeutic treatment of autoimmune diseases.
Examples of ligands which can be investigated by this method include, but are not restricted to:~
toxins and venoms: for instance, the combining site of the toxin molecule which reacts with a particular receptor in the body to give the particular symptom(s) of intoxication;
determination of mimotopes to the combining site of the ligand may lead to the development of drugs which can be used to treat envenomation by snakes and other poisonous animals without the side effects of heterologous antivenenes.
virus and other microorganism capsid molecules:
1.2~7~
for instance, the combining site on the virus coat molecule which reacts with a particular receptor on the cell membrane in the body and which allows the virus to invade and thus infect the particular cell; determination of mimotopes to this combining site may lead to the development of drugs which specifically prevent intracellular invasion by the virus and thus prevent their replication.
It is a primary obiect of this invention to detect or determine one or more short sequences of monomers (catamers) which selectively combine with a particular receptor so as to mediate its biological function. These catamers are the mimotopes of the ligand. This information is invaluable -for the design of very specific diagnostic and therapeutic agents.
The most usual group of small molecules which may be condensed together to form a catamer is the group of alpha-amino acids. However, other molecules which are consistent with a different chosen chemistry may also be used; for example, catamers formed from the specified sequential condensation of nucleotides or saccharides. Another group of small molecules would be the non-genetically coded amino acids such as beta-amino acids, which may be used to advantage to add an additional bond at specified positions within the catamer.
The method of the present invention is based on the realisation that a given receptor will specifically react with a catamer which is the mimotope for the liga~d to which the receptor is directed. It 8 L~
further relies on modern techniques of immunology to detect reaction between a receptor and its ligand when both are present.
In Canadian Patent Application 487,281 it is proposed to delineate mimotopes based on an overall length of about ~
monomers. It is now clear that the preferred method for the delineation of mimotopes is -from shorter catamers (2 or 3 monomers long) made up from all combinations of monomers from either:-(i) two sets oE monomers, which may be identical, or (ii) three sets of monomers, of which the centre monomer of the catamer is selected from a set of special chosen monomers which confer known spatial relationships on the other two monomers, the remaining monomers of the catamer coming from two sets of monomers which may be identical.
Furthermore, it has now been shown that the sensitivity of detection of binding to receptors is reduced in some instances where the monomers are synthesized in catamer preparations as disclosed in Canadian Patent Application ~o. 487,281.
We have now demonstrated that reaction is readily detected between a receptor and short mimotopes. These shortmimotopes when condensed together then bind to the receptor with either a greater affinity or with greater specificity for that receptor. This reaction can be detected even when the short mimotope presented to the receptor is as small as two monomer molecules long. By determining the op-timum short mimotope at each stage and then testing further variants, the final structure of a strongly-binding mimotope can be determined.
~;~67~
~ ccording to the present invention there is provided a method of detecting or determining the sequence of monomers which is a topographical equivalent of the ligancl which is complementary to the particular receptor of interest and prior knowledge is irrelevant about the identity, structure and sequence of the receptor or its ligand. The method comprises the steps of:-0 1. synthesizing a plurality oF catamers, each saiclcatamer being of the general formula:
D -Dl wherein Dl represents a designated monomer selected from a first set of monomers, and D~ represents a designated monomer selected from a second set of monomers which may be the same as or different to said first set of monomers; said plurality of catamers comprising catamers in which each designated monomer is systematically varied to contain members from the respective set of monomers;
2. contacting each catamer with the receptor of interest, and,
3. detecting or determining the presence or absence of binding between each catamer and said receptor.
The method may also comprise the further steps of:
a. synthesizing a further plurality of catamers, each said catamer being of the general formula:
D -D -Dl, or ~l~67C~34 D2-Dl~D3 wherein Dl and D2 ar~ as defined above, and preferably represent a combination of monomers correspQnding to a catamer which binds to said receptor, and D3 represents a designated monomer selected from a third set of monomers which may be the same as or different to either the first or the second set of monomers, and 0 b. performing steps 2 and 3 as described with the ~urther plurality of catamers.
The procedure of steps a. and b. above may be repeated to further "extend" the catamers by systematically adding further monomers to the catamers, and testing in the same manner as in step b, above.
In another important aspect, the method of this invention may comprise the steps of:
A. synthesizing a plurality of additional catamers, each said additional catamer being of the general formula:
D2--SP--Dl wherein Dl and D2 are as defined above and Sp is a spacer molecule which can modify the relative orientation of the monomers Dl and D2; and B. performing steps 2 and 3 as described above with the plurality of additional catamers.
The spacer molecule "Sp" as described above may also be systematically introduced into all possible positions of ~67~89~
the "extended" catamers referred to above, and tested in the same manner as in Step B. above.
In yet another aspect, the method of the invention may further comprise the steps of systematically replacing the monomers in any of the catamers referred to above with their optical isomers, either individually or in combinations of monomers, and again performinq steps 2 and 3 as described above.
In a further aspect, the method may further comprise the steps of systematically replacing the monomers in any of the catamers referred to above which bind with the receptor of interest, either individually or in combinations of monomers, with other monomers selected from the respective set(s) of monomers, and again performing steps 2 and 3 as described above.
It will be apparent that the method of this invention requires no previous information about the nature of the ligand and in particular it requires no foreknowledge of the sequence of monomers which make up the ligand. In fact, it is not necessary for the application of this invention to know the source or identity of the ligand to which the receptor is directed. Furthermore, this invention makes no assumptions about the nature of the ligand of the particular receptor. This method will identify mimotopes of discontinuous as well as continuous ligands. Because of the very nature of the method of the invention it will be appreciated that mimotopes may or may not consist of members of the same set of monomers which make up the ligand of which it is the mimic.
~.2~
The plurality of catamers required to be synthesized in the application of this invention may be prepared by any of the kno~n method of catamer synthesis. The preferred methods when the monomers are amino acids is to use the solid phase technique described in Canadian Patent Application No. 449,141, whereby each catamer is synthesized on a polyethylene support.
The following is a detailed description of one embodiment of the present invention when applied to the determination of a mimotope for a ligand able to bind to a receptor when that receptor is an antibody. In this context, the ligand is usually referred to as the epitope for the antibody.
Preferably the method of the present invention is carried out by screening a plurality of synthesized catamers against the antibody of interest. Ideally the antibody will be a monoclonal antibody which can be prepared by any of the usual methods. Polyclonal antiserum from humans and animals may be used if a source of monoclonal antibody with the desired characteristics is not available, however, analysis of the resulting data may be complicated because the reaction observed could be from more than one monoclonal antibody. When using polyclonal antiserum it may be necessary to reduce the antibody diversity by using techniques well known to those skilled in the art, for example iso-electric focusing, HPLC-based chromatography or affinity chroma-tography.
Current indications suggest that an epitope mimicked by a catamer which is usually about six monomers in length when the monomers come from the set of alpha-amino acids. I-t is to be understood, however, ~k :~26'~
1~
that the present invention is not restricted to sequences formed from six monomers. The ability of the 6-catamer to be the mimotope of the epitope is not critically dependent on every position having a designated monomer. It has been found that certain positions in most mimotopes are not restricted to a single designated monomer for binding with the receptor.
A. Synthesis of a plurality of catamers.
As noted above, the preferred method o-E
applying this invention is to synthesize the catamers on a solid support, In this embodiment, the plurality of catamers will all have the general formula:
Y-D2-Dl-Lk-(solid support], where "Lk" represents a llnker molecule which provides a suitable end group for condensing the monomers to the solid support. "Dl" and "D2" represent designated positions occupied by monomers which are selected from known sets of monomers; but which are altered systematically between catamers. Tt should be noted that the set of monomers used for the Dl designated position need not be the same set of monomers used for the D2 designated position. "Y" in the general formula is an end group of the catamer and may be, but is not restricted to, for example a hydrogen atom or an acetyl group. "Y" may also be another molecule which is coupled to the catamer to preserve particular characteristics of the molecular environment of a peptide bond at the amino terminal designated position.
If i is the number of members in the set of monomers to be coupled in the D1 position and ~ is the ~67~
number of members in the set of monomers to be coupled in the D2 position then a tot~l of i. ~ different catamers will be synthesized.
In the present embodiment, the support rods are prepared so that the monomers can be coupled to them by coupling an appropriate linker molecule.
For the coupling at the Dl position, each rod will be treated with a reaction mixture which contains only a single monomer such as a protected amino acid or the like. In this position each of the i monomers are coupled to 1 rods. For the coupling at the D2 position each rod is treated with a reaction mixture which contains a single monomer such as a protected amino acid or the like. Each of the ~ rods which has a particular monomer in the Dl position will have a different monomer coupled at the D2 position. In this way every combination of the members of the set(s) of monomers will be found in the i. ~ rods.
The desired end group, "Y", is then coupled using the appropriate chemistry.
After syn'hesis of the plurality of catamers any side-chain protective groups are removed from the catamers using the appropriate techniques and the rod-coupled catamers are washed.
It has been found to be a preferred embodiment of the invention to synthesize more than one set of plurality of catamers to aid in the analysis of data.
Thus, as well as synthesizing catamers with the general formula 12~i7~
Y-D~-Dl-Lk-(solid support]
as described above, additional sets of catamers may be prepared with the general formula Y-D2-Sp-D1-Lk-(solid supportl where "Sp" is a spacer molecule which may restrict the relative orientation of the monomers at the designated positions to a particular geometrical configuration(s).
The spacer molecule may also be deliberately chosen to allow a greater flexibility to the relative geometric configuration between monomers in the designated positions, Dl and D2. It should be noted that members of the set of spacer molecules may be made up from the condensation of more than one monomer. Examples of spacer molecules include, but are not restricted to glycine (approximately linear extension), beta-alanine (increased flexibility), proline (forced bend), glycyl-proline (extended bend, otherwise known as reverse bend in protein structure terminology) and o-aminobenzoic acid (a planar bend).
By analyzing the results from these sets of catamers the preferred spatial relationships between monomers in the mimotopes can be deduced as will he shown in the appropriate examples given below.
B. Testing of the plurality of catamers.
The plurality of catamers prepared as in A.
above are then contacted with the particular antibody of interest. The reaction between antibody and each catamer can then be detected by any of the usual methods, for example, radioimmunoassay (RIA). However, ~;~67~
the preferred method of detection is to use the well known enzyme-linked immunosorbent assay (ELISA).
At the end of each assay antibodies can be removed from the catamers by, Eor example, washing with a solution of 8M urea, 0.1% 2-mercaptoethanol and 0.1%
sodium dodecylsulphate followed by several washes in phosphate buffered saline. In this way the plurality of catamers may be used for -testing with many other antibodies.
C. Analyses of the data ~ n the testing of a set of catamers with antibody it has been found that certain catamers will show detectable binding with the antibody. These reacting catamers identify useful combinations of the members of the set(s) of monomers. These combinations of monomers are short mimotopes which, when extended, may bind to the antibody with a greater affinity or alters specificity. Analysis of the data is greatly facilitated by including a number of control peptides in the synthesis which aid the determination of significant responses. Further analysis of the data can be carried out in a number of ways. These include:-l. permutating each of these reacting combinations of monomers to create a list of catamers which will include mimotopes which bind to the paratope; each catamer in this list can be regarded as a possible mimotope;
2. selecting candidates from the list of reacting combinations of monomers and further synthesizing sets of catamers in which the known reacting ~2~:i7~
combination of monomers is held constant and further monomers are added systematically at either end; thus in the example above, a suitable set of such catamers would include catamers with the formulae Y-D -A -A -Lk-(solid support]
and Y-A2-Al-D3-Lk-(solid support]
where Al and A2 constitute the reacting combination of monomers from the previous results and D3 is the new designated position where each of the members of the set of monomers is systematically varied;
and 3~ combining the results from different sets of a plurality of catamers and analyzing the results to deduce a single sequence of monomers, or a small number of such sequences which would bind to the antibody of interest. Analysis of this data is possible as the reacting combinations of monomers when they are ad]acent to each other are now known, as well as the reacting combinations of monomers when they have particular geometrical configurations between them. In this way, these data can then be interpreted to predict the structure of the mimotope when bound to the antibody; this approach will be of greatest benefit when the antibody used to test the plurality of catamers is a monoclonal antibody.
The procedure given in 2. above can be repeated until no further enhancement of binding is achieved by additional extending of the mimotope.
Ideally, the sequence of the mimotope should be checked - 17 ~ 7~
by regularly synthesizing and testing replacement nets of the mimotope to obtain the optimally-binding mimotope for further extension as described in Canadian Patent Application No.
449,183.
D S nthesis of selected catamers y The selected catamers can be synthesi~ed using similar methods to those used in A. After the selected catamers have been synthesized they are reacted with the antibody of interest. It is then simple to select the catamer which binds most strongly with the antibody.
The binding of the mimotope with -the antibody can be further enhanced by synthesizing a further plurality of catamers based on the sequence of the most strongly binding mimotope. This plurality of catamers consists of adding spacer molecules (-Sp-~systematically at all positions of the mimotope; and where feasible systematically replacing each monomer of the catamer with its optical isomer. Testing of this set of catamers with the antibody will give invaluable information about the relative orientation of the monomers and their stereochemistry as required for binding with the antibody.
In Examples l, 2, 3 and 4 given below, the mimotopes are being determined for the antigen against which different monoclonal antibodies were raised. The defined set of monomers is the set of the common L-alp~a acids unless otherwise specified.
The linker molecule, -Lk-, was 3 amino-Nl(6-aminohexyl)-propanamide and the end group, Y-, was the acetyl moiety. In Example 5 below, the mimotope is determined for an antigenic determinant of human chorionic gonadotrophin which 7~8~
induced a monoclonal antibody. The linker molecule, -Lk-, is the same as that used in earlier Examples. The end group, Y-, is either ~-alanyl-~-alanine or ~-alanine. The d~fined set of monomers was extended to include the D-optical isomers of the common alpha amino acids and several unusual amino acids. In Example 6 below, the mimotope is determined for a receptor site on viruses. The linker molecule, -Lk-, is the same as for earlier Examples. The end group, Y-, is either ~-alanyl-~-alanine or ~-alanine. The defined set of monomers was extended as described for Example 5.
EXAMPLE l A monoclonal antibody was raised against sperm whale myoglobin using the usual techniques. This' monoclonal antibody was tested against a set of catamers with the general formula:
Y-D2-Dl-Lk-(solid supportl.
Three pairs of reacting monomers bound to the catamers with approximately equal response and were significantly higher than other pairs of monomers. The sequences were E-F, E-L and E-H.
A further set of catamers was synthesized which comprised all 4-catamers which could be made from the set of monomers; Glutamic acid (E), Phenylalanine (F), Histidine (H) and Leucine (L). The following catamers were found to bind significantly higher than the remaining catamers:-L-H-E-F
L-H-F-E
F-L-H-E
i2~ 8~
F~ E
H-E-F-L
This small group of short mimotopes can now become the candidates for further extensions.
EXA~lPLE 2 A monoclonal antibody was raised against sperm whale myoglobin using the usual techniques. This monoclonal antibody was tested aqainst a set of catamers with the general formula:
Y-D2-Dl-Lk-(solid support].
Three pairs of reacting monomers bound to the catamers with approximately equal response and were significantly higher than other pairs of monomers. The sequences were E-F, E-L and E-H.
Six further sets of catamers were synthesized using the pairs E-F, E-L and E-H as starting points. Using the E-F pair as an example, the catamers in each set had the general formula:-Y-E-F-Lk-(solid support], or Y-E-Sp-F-Lk-(solid support], where Sp is a spacer molecule from the set of beta-alanine, glycine and L-proline. Furthermore the D-optical isomer of both the Glutamic acid and Phenylalanine were systematically substituted for the L-optical isomer.
30The catamers which gave the best response from each set of catamers were D-Glutamic acid - L-Proline - I,-Phenylalanine L-Glutamic acid - L-Leucine, and D-Glutamic acid - L Proline - D-Histidine.
~7~8~
These results show that the monomers F and ~I were better positioned non-adjacent to E; furthermore, E and L are best positioned adjacent. The optical isomers in the catamers which gave the best binding suggest a structure for a strongly binding mimotope as set out below. It is to be noted that the sperm whale myoglobin molecule does have a region which is similar to the predicted mimotope. Obviously, this predicted mimotope becomes a candidate for further extension.
The structure below is a two dimensional representation of the spatial relationship between the amino acids, F, E, L, and H when bound to a monoclonal antibody against sperm whale myoglobin (see Example 2).
It must be noted that this is an illustration only and must not be interpreted to mean that the catamer illustrated is planar. Furthermore, the bonds ~oining F
to E and L to H are meant to represent a distance greater than that of a peptide bond.
iE -- L~
H
When this structure is compared with the X-ray crystallography structure of myoglobin, it is of considerable interest to note that the sequence -F-L-E-L- appears at positions 135 to 138 and that there are two histidine residues (at positions 81 and 82) in close proximity to the glutamic acid at position 136.
This gives considerable credence to the postulated structure of the epitope of the monoclonal antibody.
A mimotope to a monoclonal antiserum raised against Foot and Mouth Disease Virus was delineated to the sequence W-Q-M-G-H-S. A series of catamers were ~67~
synthesized in which a beta-a]anine residue was introduced systematically between monomers. The sequence ~7-Q-M-~-G-H-S gave a response which was significantly larger than the base sequence, where represents beta-alanine. It was further found that excellent binding to the antibocly was achieved with the sequences:
W-Q-M-~-~-H-S
W-Q-M-~ -H-S
which suggests that the glycine in the startinq mimotope was a spacer between two reacting elements, W-Q-M and H-S. Thus it can be clearly seen that the mimotope is made up of two parts; furthermore, the joining together of these parts is not critical for the mimotope to be able to react strongly with the antibody.
A further set of catamers were synthesized in which the D-optical isomer systematically replaced the L-optical isomer monomer in the starting mimotope. The results of testing with the antibody showed that for strongest binding, the monomers in each element should have the same optical isomer and that there was a preference for the monomers in the W-Q-~1 element to be the D-optical isomers whereas the monomers in element H-S should be L-optical isomers. These results can be interpreted to mean that the epitope to the antibody is made up of two adjacent anti-parallel chains in which the chain direction is M-Q-W and the second chain is H-S. This prediction leads to the suggestion that 0 another mimotope to the monoclonal antibody would be:-G-H-S-~-G-~7-~-M
This was synthesized and found to react with comparable binding to the antibody as the strongly binding catamer:-~67~134 W-Q-M-~-G-~I-S.
Thus, the way in which the two elements l~-Q-M and H-S
are joined toge-ther is irrelevant to the ability to combine with the antihody so long as their relative positions remain the same. The best mimotope as a potential immunogen will be one in which these elements are joined together from both s:Ldes in order to minimize conformational mobility.
~ monoclonal antibody (S~,93-7) raised against Foot and Mouth D:isease virus was tested with catamers with the general formula:-Y-D2-Dl-Lk-(solid support]
It was found that the dipeptide Q-F reacted significantly more strongly with the monoclonal antibody than with any other dipeptide.
Further sets of catamers were synthesized with the general formulae:
Y-Q-F-D3-Lk-(solid supportl and Y-D3-Q-F-IX-tsolid support]
When these sets of catamers were reacted with the antiserum it was found that the following catamers reacted significantly better with the monoclonal antibody than any of the others:-H-Q-F
N-Q-F
G-Q-F
Q-F-Q
Q-F-G
This small group of short mimotopes can now become the candidates for further extensions.
8~
EXP~IPLE _ A monoclonal antibody ~S218-4) was raised against human chorionic gonadotrophin using the usual techniques. This was tested with catamers with the general formula:-Yl-~2-Dl-Lk-lsolid support]
where Y1-- is ~-alanyl-~-alanine. It was found that the -dipeptide in the designated positions which bound most strongly to the monoclonal antibody was F-A.
Further sets of catamers were synthesized with the general formulae:-Y2-D3-Sp-F-A-Lk-(solid support]
and Yl-F-A-Sp-D3-Lk-~solid support]
where Sp is a spacer which is an element of the set [null, ~-alanine], and Y~- is the end group, ~-alanyl.
The set of monomers used in the designated position D3 was extended to include both the L- and D- optical isomers of the common alpha amino acids, and the unusual amino acids r a-amino butyric acid, ~-amino butyric acid, L-norcleucine, sarcosine, ornithine, L-norvaline, L-homophenylalanine, ~-alanine. When these sets of catamers were reacted with the monoclonal antibody it was found that the catamers which reacted strongly were:-2 Dand where PD and AD represent the D-optical isomers of proline and alanine, respectively.
Further sets of catamers were synthesized with the general formulae:-~Z~7Q~3~
2~
Y2-Da-sp-pn-F-A-Lk-(solid supportl Y1-PD-E'-A-Sp-D~-T,k-(solid support]
Y2-D4-Sp-AD-F-A-I,k-(solid support]
and Y1-AD-F-A-Sp-D4-l,k-(solid support]
where the extended set of monomers was used in ~the designated position D4. When these sets of catamers were reacted with the monoclonal antibody it was found that the catamer which reacted most strongly was:-Yl-PD-F A D
where DD represents the D-optical isomer of aspartic acia .
Further sets of catamers were synthesized with the general formulae:-Y2-D5-Sp-PD-F-~-DD-Lk-(solid support]
and Y1 PD F A DD Sp 5 ( pP
where the extended set of monomers was used in the designated position D5. When these sets of catamers were reacted with the monoclonal antibody it was found that the catamer which reacted most stronglv with the antibody was:-2 RD ~-Pn-F-A-DD
where ~ represents ~-alanine and had been included in the synthesis of the catamer as a spacer.
Pretreatment of the monoclonal antibody with human chorionic gonadotrophin completely removed the ability of the antibody to react with the catamer ~-RD-~-PD-F-A-DD thus illustrating the specificity of the mimotope.
38'~
EXAMPI,E 6 This Example illustrates the application of the invention to the detection of a mimotope to a receptor which is not an antigen to which an antibody has been raised. This Example detects mimotopes of a receptor to which a virion bincls. In this case the test system for detecting binding to catamers has to be modified. In this Example, the synthesized catamers are allowed to react with influenza virus particles (strain A-Shearwater/1/72). After reaction the catamers are washed to remove unbound virus particles. The presence of bound virus particles was detected by reacting with a polyclonal antibody (S227-1) which had been raised against the haemaglutinin of influenza virus A/Shearwater/1/72. Antibodies which had reacted with the bound virus were detected in the usual way by ELISA.
A set of catamers was synthesized with the general formula:-Yl-D2-Dl-Lk-(solid support]
where the end group, Yl-, is ~-alanyl-~-alanine. The set of monomers which was used in the designated positions Dl and D2 consisted of the D- and L- optical isomers of the common alpha amino acids. When the catamers were reacted with a suspension of influenza virions strain A/Shearwater/1/72, particles bound to dipeptides at the designated positions:-AD-K
ID
N-ID
and ~1 -I
~2~7~
where the suffix "D" indicates the D-optical isomer of the indicated amino acid. After removal of the hound virus from the catamers, the catamers were reacted with the polyclonal antibody S227-1 at the same concentration as that used to detect bound virus to ensure that the peaks found were due to binding of virus rather than binding of the polyclonal antibody.
Further sets of catamers were synthesized with the general formulae:-Y2-D3-Sp-~ -R-Lk-(solid supportl Y1-An-K-Sp-D3-Lk-(solid supportl where Yl- represents the ~ alanine end group and Sp is an element of the set of spacers, ~null,~-alanine]. The set of monomers used at the designated position D3 was the extended set as described in Example 5. When these sets of catame~s were reacted with influenza virus strain A/Shearwater/1/72, virions bound most strongly to the catamer:-Th-s Example demonstrates that the invention can be applied to the determination of mimotopes of receptor molecules and ligands in general.
Implementation of the method is limited only by the ability to detect the presence of binding to the set of catamers.
The method may also comprise the further steps of:
a. synthesizing a further plurality of catamers, each said catamer being of the general formula:
D -D -Dl, or ~l~67C~34 D2-Dl~D3 wherein Dl and D2 ar~ as defined above, and preferably represent a combination of monomers correspQnding to a catamer which binds to said receptor, and D3 represents a designated monomer selected from a third set of monomers which may be the same as or different to either the first or the second set of monomers, and 0 b. performing steps 2 and 3 as described with the ~urther plurality of catamers.
The procedure of steps a. and b. above may be repeated to further "extend" the catamers by systematically adding further monomers to the catamers, and testing in the same manner as in step b, above.
In another important aspect, the method of this invention may comprise the steps of:
A. synthesizing a plurality of additional catamers, each said additional catamer being of the general formula:
D2--SP--Dl wherein Dl and D2 are as defined above and Sp is a spacer molecule which can modify the relative orientation of the monomers Dl and D2; and B. performing steps 2 and 3 as described above with the plurality of additional catamers.
The spacer molecule "Sp" as described above may also be systematically introduced into all possible positions of ~67~89~
the "extended" catamers referred to above, and tested in the same manner as in Step B. above.
In yet another aspect, the method of the invention may further comprise the steps of systematically replacing the monomers in any of the catamers referred to above with their optical isomers, either individually or in combinations of monomers, and again performinq steps 2 and 3 as described above.
In a further aspect, the method may further comprise the steps of systematically replacing the monomers in any of the catamers referred to above which bind with the receptor of interest, either individually or in combinations of monomers, with other monomers selected from the respective set(s) of monomers, and again performing steps 2 and 3 as described above.
It will be apparent that the method of this invention requires no previous information about the nature of the ligand and in particular it requires no foreknowledge of the sequence of monomers which make up the ligand. In fact, it is not necessary for the application of this invention to know the source or identity of the ligand to which the receptor is directed. Furthermore, this invention makes no assumptions about the nature of the ligand of the particular receptor. This method will identify mimotopes of discontinuous as well as continuous ligands. Because of the very nature of the method of the invention it will be appreciated that mimotopes may or may not consist of members of the same set of monomers which make up the ligand of which it is the mimic.
~.2~
The plurality of catamers required to be synthesized in the application of this invention may be prepared by any of the kno~n method of catamer synthesis. The preferred methods when the monomers are amino acids is to use the solid phase technique described in Canadian Patent Application No. 449,141, whereby each catamer is synthesized on a polyethylene support.
The following is a detailed description of one embodiment of the present invention when applied to the determination of a mimotope for a ligand able to bind to a receptor when that receptor is an antibody. In this context, the ligand is usually referred to as the epitope for the antibody.
Preferably the method of the present invention is carried out by screening a plurality of synthesized catamers against the antibody of interest. Ideally the antibody will be a monoclonal antibody which can be prepared by any of the usual methods. Polyclonal antiserum from humans and animals may be used if a source of monoclonal antibody with the desired characteristics is not available, however, analysis of the resulting data may be complicated because the reaction observed could be from more than one monoclonal antibody. When using polyclonal antiserum it may be necessary to reduce the antibody diversity by using techniques well known to those skilled in the art, for example iso-electric focusing, HPLC-based chromatography or affinity chroma-tography.
Current indications suggest that an epitope mimicked by a catamer which is usually about six monomers in length when the monomers come from the set of alpha-amino acids. I-t is to be understood, however, ~k :~26'~
1~
that the present invention is not restricted to sequences formed from six monomers. The ability of the 6-catamer to be the mimotope of the epitope is not critically dependent on every position having a designated monomer. It has been found that certain positions in most mimotopes are not restricted to a single designated monomer for binding with the receptor.
A. Synthesis of a plurality of catamers.
As noted above, the preferred method o-E
applying this invention is to synthesize the catamers on a solid support, In this embodiment, the plurality of catamers will all have the general formula:
Y-D2-Dl-Lk-(solid support], where "Lk" represents a llnker molecule which provides a suitable end group for condensing the monomers to the solid support. "Dl" and "D2" represent designated positions occupied by monomers which are selected from known sets of monomers; but which are altered systematically between catamers. Tt should be noted that the set of monomers used for the Dl designated position need not be the same set of monomers used for the D2 designated position. "Y" in the general formula is an end group of the catamer and may be, but is not restricted to, for example a hydrogen atom or an acetyl group. "Y" may also be another molecule which is coupled to the catamer to preserve particular characteristics of the molecular environment of a peptide bond at the amino terminal designated position.
If i is the number of members in the set of monomers to be coupled in the D1 position and ~ is the ~67~
number of members in the set of monomers to be coupled in the D2 position then a tot~l of i. ~ different catamers will be synthesized.
In the present embodiment, the support rods are prepared so that the monomers can be coupled to them by coupling an appropriate linker molecule.
For the coupling at the Dl position, each rod will be treated with a reaction mixture which contains only a single monomer such as a protected amino acid or the like. In this position each of the i monomers are coupled to 1 rods. For the coupling at the D2 position each rod is treated with a reaction mixture which contains a single monomer such as a protected amino acid or the like. Each of the ~ rods which has a particular monomer in the Dl position will have a different monomer coupled at the D2 position. In this way every combination of the members of the set(s) of monomers will be found in the i. ~ rods.
The desired end group, "Y", is then coupled using the appropriate chemistry.
After syn'hesis of the plurality of catamers any side-chain protective groups are removed from the catamers using the appropriate techniques and the rod-coupled catamers are washed.
It has been found to be a preferred embodiment of the invention to synthesize more than one set of plurality of catamers to aid in the analysis of data.
Thus, as well as synthesizing catamers with the general formula 12~i7~
Y-D~-Dl-Lk-(solid support]
as described above, additional sets of catamers may be prepared with the general formula Y-D2-Sp-D1-Lk-(solid supportl where "Sp" is a spacer molecule which may restrict the relative orientation of the monomers at the designated positions to a particular geometrical configuration(s).
The spacer molecule may also be deliberately chosen to allow a greater flexibility to the relative geometric configuration between monomers in the designated positions, Dl and D2. It should be noted that members of the set of spacer molecules may be made up from the condensation of more than one monomer. Examples of spacer molecules include, but are not restricted to glycine (approximately linear extension), beta-alanine (increased flexibility), proline (forced bend), glycyl-proline (extended bend, otherwise known as reverse bend in protein structure terminology) and o-aminobenzoic acid (a planar bend).
By analyzing the results from these sets of catamers the preferred spatial relationships between monomers in the mimotopes can be deduced as will he shown in the appropriate examples given below.
B. Testing of the plurality of catamers.
The plurality of catamers prepared as in A.
above are then contacted with the particular antibody of interest. The reaction between antibody and each catamer can then be detected by any of the usual methods, for example, radioimmunoassay (RIA). However, ~;~67~
the preferred method of detection is to use the well known enzyme-linked immunosorbent assay (ELISA).
At the end of each assay antibodies can be removed from the catamers by, Eor example, washing with a solution of 8M urea, 0.1% 2-mercaptoethanol and 0.1%
sodium dodecylsulphate followed by several washes in phosphate buffered saline. In this way the plurality of catamers may be used for -testing with many other antibodies.
C. Analyses of the data ~ n the testing of a set of catamers with antibody it has been found that certain catamers will show detectable binding with the antibody. These reacting catamers identify useful combinations of the members of the set(s) of monomers. These combinations of monomers are short mimotopes which, when extended, may bind to the antibody with a greater affinity or alters specificity. Analysis of the data is greatly facilitated by including a number of control peptides in the synthesis which aid the determination of significant responses. Further analysis of the data can be carried out in a number of ways. These include:-l. permutating each of these reacting combinations of monomers to create a list of catamers which will include mimotopes which bind to the paratope; each catamer in this list can be regarded as a possible mimotope;
2. selecting candidates from the list of reacting combinations of monomers and further synthesizing sets of catamers in which the known reacting ~2~:i7~
combination of monomers is held constant and further monomers are added systematically at either end; thus in the example above, a suitable set of such catamers would include catamers with the formulae Y-D -A -A -Lk-(solid support]
and Y-A2-Al-D3-Lk-(solid support]
where Al and A2 constitute the reacting combination of monomers from the previous results and D3 is the new designated position where each of the members of the set of monomers is systematically varied;
and 3~ combining the results from different sets of a plurality of catamers and analyzing the results to deduce a single sequence of monomers, or a small number of such sequences which would bind to the antibody of interest. Analysis of this data is possible as the reacting combinations of monomers when they are ad]acent to each other are now known, as well as the reacting combinations of monomers when they have particular geometrical configurations between them. In this way, these data can then be interpreted to predict the structure of the mimotope when bound to the antibody; this approach will be of greatest benefit when the antibody used to test the plurality of catamers is a monoclonal antibody.
The procedure given in 2. above can be repeated until no further enhancement of binding is achieved by additional extending of the mimotope.
Ideally, the sequence of the mimotope should be checked - 17 ~ 7~
by regularly synthesizing and testing replacement nets of the mimotope to obtain the optimally-binding mimotope for further extension as described in Canadian Patent Application No.
449,183.
D S nthesis of selected catamers y The selected catamers can be synthesi~ed using similar methods to those used in A. After the selected catamers have been synthesized they are reacted with the antibody of interest. It is then simple to select the catamer which binds most strongly with the antibody.
The binding of the mimotope with -the antibody can be further enhanced by synthesizing a further plurality of catamers based on the sequence of the most strongly binding mimotope. This plurality of catamers consists of adding spacer molecules (-Sp-~systematically at all positions of the mimotope; and where feasible systematically replacing each monomer of the catamer with its optical isomer. Testing of this set of catamers with the antibody will give invaluable information about the relative orientation of the monomers and their stereochemistry as required for binding with the antibody.
In Examples l, 2, 3 and 4 given below, the mimotopes are being determined for the antigen against which different monoclonal antibodies were raised. The defined set of monomers is the set of the common L-alp~a acids unless otherwise specified.
The linker molecule, -Lk-, was 3 amino-Nl(6-aminohexyl)-propanamide and the end group, Y-, was the acetyl moiety. In Example 5 below, the mimotope is determined for an antigenic determinant of human chorionic gonadotrophin which 7~8~
induced a monoclonal antibody. The linker molecule, -Lk-, is the same as that used in earlier Examples. The end group, Y-, is either ~-alanyl-~-alanine or ~-alanine. The d~fined set of monomers was extended to include the D-optical isomers of the common alpha amino acids and several unusual amino acids. In Example 6 below, the mimotope is determined for a receptor site on viruses. The linker molecule, -Lk-, is the same as for earlier Examples. The end group, Y-, is either ~-alanyl-~-alanine or ~-alanine. The defined set of monomers was extended as described for Example 5.
EXAMPLE l A monoclonal antibody was raised against sperm whale myoglobin using the usual techniques. This' monoclonal antibody was tested against a set of catamers with the general formula:
Y-D2-Dl-Lk-(solid supportl.
Three pairs of reacting monomers bound to the catamers with approximately equal response and were significantly higher than other pairs of monomers. The sequences were E-F, E-L and E-H.
A further set of catamers was synthesized which comprised all 4-catamers which could be made from the set of monomers; Glutamic acid (E), Phenylalanine (F), Histidine (H) and Leucine (L). The following catamers were found to bind significantly higher than the remaining catamers:-L-H-E-F
L-H-F-E
F-L-H-E
i2~ 8~
F~ E
H-E-F-L
This small group of short mimotopes can now become the candidates for further extensions.
EXA~lPLE 2 A monoclonal antibody was raised against sperm whale myoglobin using the usual techniques. This monoclonal antibody was tested aqainst a set of catamers with the general formula:
Y-D2-Dl-Lk-(solid support].
Three pairs of reacting monomers bound to the catamers with approximately equal response and were significantly higher than other pairs of monomers. The sequences were E-F, E-L and E-H.
Six further sets of catamers were synthesized using the pairs E-F, E-L and E-H as starting points. Using the E-F pair as an example, the catamers in each set had the general formula:-Y-E-F-Lk-(solid support], or Y-E-Sp-F-Lk-(solid support], where Sp is a spacer molecule from the set of beta-alanine, glycine and L-proline. Furthermore the D-optical isomer of both the Glutamic acid and Phenylalanine were systematically substituted for the L-optical isomer.
30The catamers which gave the best response from each set of catamers were D-Glutamic acid - L-Proline - I,-Phenylalanine L-Glutamic acid - L-Leucine, and D-Glutamic acid - L Proline - D-Histidine.
~7~8~
These results show that the monomers F and ~I were better positioned non-adjacent to E; furthermore, E and L are best positioned adjacent. The optical isomers in the catamers which gave the best binding suggest a structure for a strongly binding mimotope as set out below. It is to be noted that the sperm whale myoglobin molecule does have a region which is similar to the predicted mimotope. Obviously, this predicted mimotope becomes a candidate for further extension.
The structure below is a two dimensional representation of the spatial relationship between the amino acids, F, E, L, and H when bound to a monoclonal antibody against sperm whale myoglobin (see Example 2).
It must be noted that this is an illustration only and must not be interpreted to mean that the catamer illustrated is planar. Furthermore, the bonds ~oining F
to E and L to H are meant to represent a distance greater than that of a peptide bond.
iE -- L~
H
When this structure is compared with the X-ray crystallography structure of myoglobin, it is of considerable interest to note that the sequence -F-L-E-L- appears at positions 135 to 138 and that there are two histidine residues (at positions 81 and 82) in close proximity to the glutamic acid at position 136.
This gives considerable credence to the postulated structure of the epitope of the monoclonal antibody.
A mimotope to a monoclonal antiserum raised against Foot and Mouth Disease Virus was delineated to the sequence W-Q-M-G-H-S. A series of catamers were ~67~
synthesized in which a beta-a]anine residue was introduced systematically between monomers. The sequence ~7-Q-M-~-G-H-S gave a response which was significantly larger than the base sequence, where represents beta-alanine. It was further found that excellent binding to the antibocly was achieved with the sequences:
W-Q-M-~-~-H-S
W-Q-M-~ -H-S
which suggests that the glycine in the startinq mimotope was a spacer between two reacting elements, W-Q-M and H-S. Thus it can be clearly seen that the mimotope is made up of two parts; furthermore, the joining together of these parts is not critical for the mimotope to be able to react strongly with the antibody.
A further set of catamers were synthesized in which the D-optical isomer systematically replaced the L-optical isomer monomer in the starting mimotope. The results of testing with the antibody showed that for strongest binding, the monomers in each element should have the same optical isomer and that there was a preference for the monomers in the W-Q-~1 element to be the D-optical isomers whereas the monomers in element H-S should be L-optical isomers. These results can be interpreted to mean that the epitope to the antibody is made up of two adjacent anti-parallel chains in which the chain direction is M-Q-W and the second chain is H-S. This prediction leads to the suggestion that 0 another mimotope to the monoclonal antibody would be:-G-H-S-~-G-~7-~-M
This was synthesized and found to react with comparable binding to the antibody as the strongly binding catamer:-~67~134 W-Q-M-~-G-~I-S.
Thus, the way in which the two elements l~-Q-M and H-S
are joined toge-ther is irrelevant to the ability to combine with the antihody so long as their relative positions remain the same. The best mimotope as a potential immunogen will be one in which these elements are joined together from both s:Ldes in order to minimize conformational mobility.
~ monoclonal antibody (S~,93-7) raised against Foot and Mouth D:isease virus was tested with catamers with the general formula:-Y-D2-Dl-Lk-(solid support]
It was found that the dipeptide Q-F reacted significantly more strongly with the monoclonal antibody than with any other dipeptide.
Further sets of catamers were synthesized with the general formulae:
Y-Q-F-D3-Lk-(solid supportl and Y-D3-Q-F-IX-tsolid support]
When these sets of catamers were reacted with the antiserum it was found that the following catamers reacted significantly better with the monoclonal antibody than any of the others:-H-Q-F
N-Q-F
G-Q-F
Q-F-Q
Q-F-G
This small group of short mimotopes can now become the candidates for further extensions.
8~
EXP~IPLE _ A monoclonal antibody ~S218-4) was raised against human chorionic gonadotrophin using the usual techniques. This was tested with catamers with the general formula:-Yl-~2-Dl-Lk-lsolid support]
where Y1-- is ~-alanyl-~-alanine. It was found that the -dipeptide in the designated positions which bound most strongly to the monoclonal antibody was F-A.
Further sets of catamers were synthesized with the general formulae:-Y2-D3-Sp-F-A-Lk-(solid support]
and Yl-F-A-Sp-D3-Lk-~solid support]
where Sp is a spacer which is an element of the set [null, ~-alanine], and Y~- is the end group, ~-alanyl.
The set of monomers used in the designated position D3 was extended to include both the L- and D- optical isomers of the common alpha amino acids, and the unusual amino acids r a-amino butyric acid, ~-amino butyric acid, L-norcleucine, sarcosine, ornithine, L-norvaline, L-homophenylalanine, ~-alanine. When these sets of catamers were reacted with the monoclonal antibody it was found that the catamers which reacted strongly were:-2 Dand where PD and AD represent the D-optical isomers of proline and alanine, respectively.
Further sets of catamers were synthesized with the general formulae:-~Z~7Q~3~
2~
Y2-Da-sp-pn-F-A-Lk-(solid supportl Y1-PD-E'-A-Sp-D~-T,k-(solid support]
Y2-D4-Sp-AD-F-A-I,k-(solid support]
and Y1-AD-F-A-Sp-D4-l,k-(solid support]
where the extended set of monomers was used in ~the designated position D4. When these sets of catamers were reacted with the monoclonal antibody it was found that the catamer which reacted most strongly was:-Yl-PD-F A D
where DD represents the D-optical isomer of aspartic acia .
Further sets of catamers were synthesized with the general formulae:-Y2-D5-Sp-PD-F-~-DD-Lk-(solid support]
and Y1 PD F A DD Sp 5 ( pP
where the extended set of monomers was used in the designated position D5. When these sets of catamers were reacted with the monoclonal antibody it was found that the catamer which reacted most stronglv with the antibody was:-2 RD ~-Pn-F-A-DD
where ~ represents ~-alanine and had been included in the synthesis of the catamer as a spacer.
Pretreatment of the monoclonal antibody with human chorionic gonadotrophin completely removed the ability of the antibody to react with the catamer ~-RD-~-PD-F-A-DD thus illustrating the specificity of the mimotope.
38'~
EXAMPI,E 6 This Example illustrates the application of the invention to the detection of a mimotope to a receptor which is not an antigen to which an antibody has been raised. This Example detects mimotopes of a receptor to which a virion bincls. In this case the test system for detecting binding to catamers has to be modified. In this Example, the synthesized catamers are allowed to react with influenza virus particles (strain A-Shearwater/1/72). After reaction the catamers are washed to remove unbound virus particles. The presence of bound virus particles was detected by reacting with a polyclonal antibody (S227-1) which had been raised against the haemaglutinin of influenza virus A/Shearwater/1/72. Antibodies which had reacted with the bound virus were detected in the usual way by ELISA.
A set of catamers was synthesized with the general formula:-Yl-D2-Dl-Lk-(solid support]
where the end group, Yl-, is ~-alanyl-~-alanine. The set of monomers which was used in the designated positions Dl and D2 consisted of the D- and L- optical isomers of the common alpha amino acids. When the catamers were reacted with a suspension of influenza virions strain A/Shearwater/1/72, particles bound to dipeptides at the designated positions:-AD-K
ID
N-ID
and ~1 -I
~2~7~
where the suffix "D" indicates the D-optical isomer of the indicated amino acid. After removal of the hound virus from the catamers, the catamers were reacted with the polyclonal antibody S227-1 at the same concentration as that used to detect bound virus to ensure that the peaks found were due to binding of virus rather than binding of the polyclonal antibody.
Further sets of catamers were synthesized with the general formulae:-Y2-D3-Sp-~ -R-Lk-(solid supportl Y1-An-K-Sp-D3-Lk-(solid supportl where Yl- represents the ~ alanine end group and Sp is an element of the set of spacers, ~null,~-alanine]. The set of monomers used at the designated position D3 was the extended set as described in Example 5. When these sets of catame~s were reacted with influenza virus strain A/Shearwater/1/72, virions bound most strongly to the catamer:-Th-s Example demonstrates that the invention can be applied to the determination of mimotopes of receptor molecules and ligands in general.
Implementation of the method is limited only by the ability to detect the presence of binding to the set of catamers.
Claims (8)
1. A method of detecting or determining the sequence of monomers which is a topographical equivalent of the ligand which is complementary to a particular receptor of interest, the method comprising the steps of:-
1. synthesizing a plurality of catamers, each said catamer being of the general formula:
wherein D1 represents a designated monomer selected from a first set of monomers, and D2 represents a designated monomer selected from a second set of monomers which may be the same as or different to said first set of monomers;
said plurality of catamers comprising catamers in which each designated monomer is systematically varied to contain members from the respective set of monomers;
2. contacting each catamer with the receptor of interest, and, 3. detecting or determining the presence or absence of binding between each catamer and said receptor.
wherein D1 represents a designated monomer selected from a first set of monomers, and D2 represents a designated monomer selected from a second set of monomers which may be the same as or different to said first set of monomers;
said plurality of catamers comprising catamers in which each designated monomer is systematically varied to contain members from the respective set of monomers;
2. contacting each catamer with the receptor of interest, and, 3. detecting or determining the presence or absence of binding between each catamer and said receptor.
2. A method according to claim 1, comprising the further steps of:-a. synthesizing a further plurality of catamers, each said catamer being of the general formula:
D3-D2-D1, or wherein D1 and D2 are as defined above, in claim 1, and D3 represents a designated monomer selected from a third set of monomers which may be the same as or different to either the first or the second set of monomers, and b. performing steps 2 and 3 as defined in claim 1 with said further plurality of catamers.
D3-D2-D1, or wherein D1 and D2 are as defined above, in claim 1, and D3 represents a designated monomer selected from a third set of monomers which may be the same as or different to either the first or the second set of monomers, and b. performing steps 2 and 3 as defined in claim 1 with said further plurality of catamers.
3. A method according to claim 2, wherein steps a. and b.
are repeated with the systematic addition of further monomers to the catamers.
are repeated with the systematic addition of further monomers to the catamers.
4. A method according to claim 1 comprising the further steps of:-A. synthesizing a plurality of additional catamers, each said additional catamer being of the general formula:
wherein D1 and D2 are as defined in claim 1 and Sp is a spacer molecule which can modify the relative orientation of the monomers D1 and D2; and B. performing steps 2 and 3 as defined in claim 1 with said plurality of additional catamers.
wherein D1 and D2 are as defined in claim 1 and Sp is a spacer molecule which can modify the relative orientation of the monomers D1 and D2; and B. performing steps 2 and 3 as defined in claim 1 with said plurality of additional catamers.
5. A method according to claim 2 or claim 3, wherein steps a. and b. are repeated with the systematic introduction of a spacer molecule Sp as defined in claim 4 into all possible positions of the further pluralities o-f catamers as defined in claim 2 or claim 3,.
6. A method according to any one of claims 1 to 3, comprising the further step of systematically replacing the monomers in any of the catamers referred to above with their optical isomers, either individually or in combinations of monomers, and again performing steps 2 and 3 as defined in claim 1.
7 A method according to any one of claims 1 to 3, comprising the further step of systematically replacing the monomers in any of the catamers which bind with the receptor of interest, either individually or in combinations of monomers, with other monomers selected from the respective set(s) of monomers, and again performing steps 2 and 3 as defined in claim 1.
8. A method according to claim 1, wherein each of said plurality of catamers is synthesized on a solid support, and has the general formula:-Y-D2-D1-Lk-(solid support]
wherein D1 and D2 are as defined in claim 1, Lk represents a linker molecule, and Y is an end group of the catamer.
9. A method according to claim 4, wherein each of said plurality of additional catamers is synthesized on a solid support, and has the general formula:-Y-D2-SP-D1-Lk-(solid support]
wherein D1 and D2 are as defined in claim 1, Sp is as defined in claim 4, and Lk and Y are as defined in
8. A method according to claim 1, wherein each of said plurality of catamers is synthesized on a solid support, and has the general formula:-Y-D2-D1-Lk-(solid support]
wherein D1 and D2 are as defined in claim 1, Lk represents a linker molecule, and Y is an end group of the catamer.
9. A method according to claim 4, wherein each of said plurality of additional catamers is synthesized on a solid support, and has the general formula:-Y-D2-SP-D1-Lk-(solid support]
wherein D1 and D2 are as defined in claim 1, Sp is as defined in claim 4, and Lk and Y are as defined in
claim 8.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPH00240/85 | 1985-04-22 | ||
| AUPH024085 | 1985-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1267084A true CA1267084A (en) | 1990-03-27 |
Family
ID=3771065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000507185A Expired - Lifetime CA1267084A (en) | 1985-04-22 | 1986-04-21 | Method for determining mimotopes |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4833092A (en) |
| EP (1) | EP0220245B1 (en) |
| JP (1) | JPS62502568A (en) |
| AT (1) | ATE78097T1 (en) |
| CA (1) | CA1267084A (en) |
| DE (1) | DE3685930T2 (en) |
| DK (1) | DK165197C (en) |
| MY (1) | MY102884A (en) |
| NO (1) | NO168793C (en) |
| NZ (1) | NZ215865A (en) |
Families Citing this family (219)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866363A (en) | 1985-08-28 | 1999-02-02 | Pieczenik; George | Method and means for sorting and identifying biological information |
| JP2525798B2 (en) * | 1987-03-12 | 1996-08-21 | 第一製薬株式会社 | Peptide derivative |
| US5300425A (en) * | 1987-10-13 | 1994-04-05 | Terrapin Technologies, Inc. | Method to produce immunodiagnostic reagents |
| US5217869A (en) * | 1987-10-13 | 1993-06-08 | Terrapin Technologies, Inc. | Method to produce immunodiagnostic reagents |
| US5200320A (en) * | 1987-12-07 | 1993-04-06 | National Jewish Center For Immunology And Respiratory Medicine | Method for identifying useful polypeptide vaccines |
| US5266684A (en) * | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
| US6416952B1 (en) | 1989-06-07 | 2002-07-09 | Affymetrix, Inc. | Photolithographic and other means for manufacturing arrays |
| US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5424186A (en) * | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US6309822B1 (en) | 1989-06-07 | 2001-10-30 | Affymetrix, Inc. | Method for comparing copy number of nucleic acid sequences |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US6551784B2 (en) | 1989-06-07 | 2003-04-22 | Affymetrix Inc | Method of comparing nucleic acid sequences |
| US5547839A (en) * | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US6406844B1 (en) | 1989-06-07 | 2002-06-18 | Affymetrix, Inc. | Very large scale immobilized polymer synthesis |
| US6955915B2 (en) * | 1989-06-07 | 2005-10-18 | Affymetrix, Inc. | Apparatus comprising polymers |
| US6346413B1 (en) | 1989-06-07 | 2002-02-12 | Affymetrix, Inc. | Polymer arrays |
| US5925525A (en) * | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
| US6919211B1 (en) * | 1989-06-07 | 2005-07-19 | Affymetrix, Inc. | Polypeptide arrays |
| JP3443119B2 (en) | 1989-08-07 | 2003-09-02 | ペプテック リミテッド | Tumor necrosis factor binding ligand |
| US20030225254A1 (en) * | 1989-08-07 | 2003-12-04 | Rathjen Deborah Ann | Tumour necrosis factor binding ligands |
| US5959087A (en) * | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
| US6506558B1 (en) | 1990-03-07 | 2003-01-14 | Affymetrix Inc. | Very large scale immobilized polymer synthesis |
| US6759392B1 (en) * | 1990-06-11 | 2004-07-06 | Gilead Sciences, Inc. | High affinity RNA ligands of basic fibroblast growth factor |
| US5707796A (en) * | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
| US5503978A (en) * | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| US5543293A (en) * | 1990-06-11 | 1996-08-06 | Nexstar Pharmaceuticals, Inc. | DNA ligands of thrombin |
| US6177557B1 (en) | 1990-06-11 | 2001-01-23 | Nexstar Pharmaceuticals, Inc. | High affinity ligands of basic fibroblast growth factor and thrombin |
| US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5650489A (en) * | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| US5476839A (en) * | 1990-07-10 | 1995-12-19 | Incyte Pharmaceuticals, Inc. | Basophil granule proteins |
| US6197529B1 (en) | 1990-11-21 | 2001-03-06 | Torrey Pines Institute For Molecular Studies | Linear substituted oligoalkyleneimine libraries |
| EP0512112B1 (en) * | 1990-11-27 | 1997-05-28 | Biogen, Inc. | Anti cd-4 antibodies blocking hiv-induced syncytia |
| EP0834576B1 (en) | 1990-12-06 | 2002-01-16 | Affymetrix, Inc. (a Delaware Corporation) | Detection of nucleic acid sequences |
| TW304957B (en) * | 1991-06-18 | 1997-05-11 | Lilly Co Eli | |
| EP0673435A1 (en) * | 1991-08-23 | 1995-09-27 | Isis Pharmaceuticals, Inc. | Synthetic unrandomization of oligomer fragments |
| US5747253A (en) * | 1991-08-23 | 1998-05-05 | Isis Pharmaceuticals, Inc. | Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding |
| US5698391A (en) * | 1991-08-23 | 1997-12-16 | Isis Pharmaceuticals, Inc. | Methods for synthetic unrandomization of oligomer fragments |
| DK0604552T3 (en) * | 1991-09-18 | 1997-08-04 | Affymax Tech Nv | Process for the synthesis of different assemblies of oligomers |
| US5639603A (en) * | 1991-09-18 | 1997-06-17 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
| US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US5733731A (en) * | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
| US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| WO1993009668A1 (en) * | 1991-11-22 | 1993-05-27 | Affymax Technology N.V. | Combinatorial strategies for polymer synthesis |
| US6943034B1 (en) | 1991-11-22 | 2005-09-13 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
| US6864101B1 (en) | 1991-11-22 | 2005-03-08 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
| US6468740B1 (en) | 1992-11-05 | 2002-10-22 | Affymetrix, Inc. | Cyclic and substituted immobilized molecular synthesis |
| US5871734A (en) * | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| US5932214A (en) * | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| CA2140257A1 (en) * | 1992-07-27 | 1994-02-03 | Lawrence M. Kauvar | Sorbent families |
| US5565324A (en) * | 1992-10-01 | 1996-10-15 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
| US6503759B1 (en) | 1992-10-01 | 2003-01-07 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
| US5721099A (en) * | 1992-10-01 | 1998-02-24 | Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
| EP0682529B2 (en) * | 1993-02-09 | 2005-12-28 | Biogen Idec MA, Inc. | Antibody for the treatment of insulin dependent diabetes |
| US5367053A (en) * | 1993-05-19 | 1994-11-22 | Houghten Pharmaceuticals, Inc. | Opioid peptide inhibitors |
| US6632613B1 (en) | 1993-06-02 | 2003-10-14 | University Of Utah Research Foundation | Compositions and kits for fluorescence polarization assay of large molecules |
| US5846731A (en) * | 1993-06-17 | 1998-12-08 | Torry Pines Institute For Molecular Studies | Peralkylated oligopeptide mixtures |
| US5480971A (en) * | 1993-06-17 | 1996-01-02 | Houghten Pharmaceuticals, Inc. | Peralkylated oligopeptide mixtures |
| US5380668A (en) * | 1993-07-06 | 1995-01-10 | University Of Utah Research Foundation | Compounds having the antigenicity of hCG |
| US6576419B1 (en) * | 1993-07-23 | 2003-06-10 | University Of Utah Research Foundation | Assay procedure using fluorogenic tracers |
| CN1154640C (en) * | 1993-10-01 | 2004-06-23 | 纽约市哥伦比亚大学理事 | Complex combinatorial chemical libraries encoded with tags |
| WO1995010296A1 (en) * | 1993-10-12 | 1995-04-20 | Glycomed Incorporated | A library of glyco-peptides useful for identification of cell adhesion inhibitors |
| US5503805A (en) * | 1993-11-02 | 1996-04-02 | Affymax Technologies N.V. | Apparatus and method for parallel coupling reactions |
| US6165778A (en) * | 1993-11-02 | 2000-12-26 | Affymax Technologies N.V. | Reaction vessel agitation apparatus |
| US6287787B1 (en) | 1993-11-24 | 2001-09-11 | Torrey Pines Institute For Molecular Studies | Dimeric oligopeptide mixture sets |
| WO1995019567A1 (en) * | 1994-01-13 | 1995-07-20 | The Trustees Of Columbia University In The City Of New York | Synthetic receptors, libraries and uses thereof |
| US5593853A (en) * | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
| US6936477B2 (en) * | 1994-04-13 | 2005-08-30 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
| US5846841A (en) * | 1994-05-20 | 1998-12-08 | Selectide Corporation | Motif Libraries |
| US7323298B1 (en) | 1994-06-17 | 2008-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Microarray for determining the relative abundances of polynuceotide sequences |
| US7378236B1 (en) | 1994-06-17 | 2008-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method for analyzing gene expression patterns |
| US5582997A (en) * | 1994-08-24 | 1996-12-10 | Torrey Pines Institute For Molecular Studies | Lysine/leucine polypeptides, mixture sets and libraries thereof |
| US5645996A (en) * | 1994-08-24 | 1997-07-08 | Torrey Pines Institute For Molecular Studies | Melittin-related polypeptides, mixture sets and libraries thereof |
| US5885782A (en) * | 1994-09-13 | 1999-03-23 | Nce Pharmaceuticals, Inc. | Synthetic antibiotics |
| US6020312A (en) * | 1994-09-13 | 2000-02-01 | Nce Pharmaceuticals, Inc. | Synthetic antibiotics |
| US5602097A (en) * | 1994-09-13 | 1997-02-11 | Ceres Technologies, Inc. | Synthetic antibiotics |
| US8236493B2 (en) * | 1994-10-21 | 2012-08-07 | Affymetrix, Inc. | Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA |
| US5958792A (en) * | 1995-06-07 | 1999-09-28 | Chiron Corporation | Combinatorial libraries of substrate-bound cyclic organic compounds |
| US5747458A (en) * | 1995-06-07 | 1998-05-05 | Chiron Corporation | Urokinase receptor ligands |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | Nucleic acid analysis techniques |
| US6183988B1 (en) | 1996-10-02 | 2001-02-06 | The General Hospital Corporation | Leukocyte-specific protein and gene, and methods of use thereof |
| US6096496A (en) | 1997-06-19 | 2000-08-01 | Frankel; Robert D. | Supports incorporating vertical cavity emitting lasers and tracking apparatus for use in combinatorial synthesis |
| US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| ES2252999T3 (en) * | 1998-08-31 | 2006-05-16 | Biogen Idec Ma Inc. | MODULATION OF EFFECT AND MEMORY T-CELLS WITH A CD2 LINK. |
| CA2343579C (en) | 1998-09-14 | 2012-05-29 | Gregory R. Mundy | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| US6545264B1 (en) | 1998-10-30 | 2003-04-08 | Affymetrix, Inc. | Systems and methods for high performance scanning |
| ATE296350T1 (en) * | 1999-06-14 | 2005-06-15 | Genentech Inc | STRUCTURED PEPTIDE SCAFFOLD FOR DISPLAYING TURNED LIBRARIES ON PHAGE |
| US20030166003A1 (en) * | 1999-06-14 | 2003-09-04 | Cochran Andrea G. | Structured peptide scaffold for displaying turn libraries on phage |
| CA2394431C (en) | 1999-12-16 | 2015-06-30 | Jane Relton | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| EP1930023A3 (en) | 2001-04-09 | 2008-08-06 | East Carolina University | Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
| US20020169128A1 (en) * | 2001-04-09 | 2002-11-14 | Geroge Sigounas | Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
| US6914123B2 (en) * | 2001-04-17 | 2005-07-05 | Genentech, Inc. | Hairpin peptides with a novel structural motif and methods relating thereto |
| US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| US20050107595A1 (en) * | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| DK2000545T3 (en) | 2001-06-20 | 2011-11-28 | Genentech Inc | Compositions and methods for diagnosis and treatment of lung tumor |
| US7803915B2 (en) * | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
| US20030013208A1 (en) * | 2001-07-13 | 2003-01-16 | Milagen, Inc. | Information enhanced antibody arrays |
| WO2003009740A2 (en) * | 2001-07-24 | 2003-02-06 | Biogen Idec Ma Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
| EP2174953A1 (en) | 2001-09-18 | 2010-04-14 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| EP1326076A3 (en) * | 2001-10-26 | 2004-01-28 | Millenium Pharmaceuticals, Inc. | Methods for indentification of ligands or modulators of 2871 receptor, a g-protein coupled receptor |
| AU2002367318B2 (en) | 2002-01-02 | 2007-07-12 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| AU2003230603A1 (en) | 2002-03-08 | 2003-09-22 | Board Of Regents, The University Of Texas System | Controlled modulation of amino acid side chain length of peptide antigens |
| JP2005536190A (en) | 2002-04-16 | 2005-12-02 | ジェネンテック・インコーポレーテッド | Compositions and methods for tumor diagnosis and treatment |
| EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
| SI1540335T1 (en) | 2002-08-19 | 2010-10-29 | Helicon Therapeutics Inc | Screening methods for cognitive enhancers |
| AU2003243398A1 (en) * | 2002-08-29 | 2004-03-19 | Genentech, Inc. | Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor |
| US6910785B2 (en) * | 2003-01-22 | 2005-06-28 | Cooper Technologies Company | Industrial luminaire with prismatic refractor |
| US20040185499A1 (en) * | 2003-03-20 | 2004-09-23 | Jolley Michael E. | Method of epitope scanning using fluorescence polarization |
| US8613922B2 (en) | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| DE10329087B4 (en) * | 2003-06-27 | 2014-02-13 | Biomedical International R + D Gmbh | Antigen-containing microspheres for allergy therapy |
| EP2784084B2 (en) | 2003-07-08 | 2023-10-04 | Novartis Pharma AG | Antagonist antibodies to IL-17A/F heterologous polypeptides |
| US20050095648A1 (en) * | 2003-10-30 | 2005-05-05 | Mario Geysen | Method for designing linear epitopes and algorithm therefor and polypeptide epitopes |
| EP2476707B1 (en) | 2003-11-14 | 2017-05-24 | Children's Medical Center Corporation | Self-cleaving ribozymes and uses thereof |
| ES2493016T3 (en) | 2003-11-17 | 2014-09-11 | Genentech, Inc. | Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or a cytotoxic agent and methods for the treatment of tumors of hematopoietic origin |
| CA2529694A1 (en) | 2003-12-10 | 2005-07-07 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
| BRPI0507404A (en) * | 2004-02-06 | 2007-06-26 | Astellas Us Llc | method of treating an individual who has psoriasis and kit |
| US7754769B2 (en) | 2004-03-02 | 2010-07-13 | Mcgill University | Compositions and methods for preventing or treating an inflammatory response |
| KR20070011558A (en) * | 2004-05-04 | 2007-01-24 | 제네상스 파머슈티컬스, 아이엔씨. | Haplotype markers and methods of using the same to determine response to treatment |
| US7662921B2 (en) * | 2004-05-07 | 2010-02-16 | Astellas Us Llc | Methods of treating viral disorders |
| CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| AU2005306399B2 (en) * | 2004-11-19 | 2012-02-09 | Biogen Ma Inc. | Treatment for multiple sclerosis |
| AU2006223498A1 (en) | 2005-03-10 | 2006-09-21 | Genentech, Inc. | Methods and compositions for modulating vascular integrity |
| KR20080051113A (en) | 2005-05-02 | 2008-06-10 | 콜드스프링하버러보러토리 | Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster |
| EP1871163A2 (en) | 2005-06-06 | 2008-01-02 | Genentech, Inc. | Transgenic models for different genes and their use for gene characterization |
| WO2006138429A2 (en) | 2005-06-16 | 2006-12-28 | The Feinstein Institute For Medical Research | Antibodies against hmgb1 and fragments thereof |
| WO2007021423A2 (en) | 2005-08-15 | 2007-02-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| US8945573B2 (en) | 2005-09-08 | 2015-02-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Targeted identification of immunogenic peptides |
| JP2009516514A (en) | 2005-11-21 | 2009-04-23 | ジェネンテック・インコーポレーテッド | Novel gene disruptions, compositions and methods related thereto |
| ES2547689T3 (en) | 2005-12-02 | 2015-10-08 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling that involve antibodies that bind to IL-22 and IL-22R |
| CA2638821A1 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
| EP2614839A3 (en) | 2006-04-05 | 2015-01-28 | Genentech, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
| EP2010662A2 (en) | 2006-04-19 | 2009-01-07 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
| WO2007134132A2 (en) * | 2006-05-12 | 2007-11-22 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors |
| US20080015145A1 (en) * | 2006-07-11 | 2008-01-17 | Maria Gyongyossy-Issa | Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions |
| US8586006B2 (en) | 2006-08-09 | 2013-11-19 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
| JP2010503407A (en) | 2006-09-12 | 2010-02-04 | ジェネンテック・インコーポレーテッド | Methods and compositions for diagnosis and treatment of cancer |
| CN101663407B (en) | 2007-02-22 | 2017-08-08 | 健泰科生物技术公司 | method for detecting inflammatory bowel disease |
| NZ584330A (en) * | 2007-10-04 | 2013-01-25 | Bionomics Ltd | Markers of endothelial cells and uses thereof |
| EP3360567A1 (en) | 2007-11-07 | 2018-08-15 | Genentech, Inc. | Amp for use in treating microbial disorders |
| US9182406B2 (en) * | 2008-08-04 | 2015-11-10 | Biodesy, Inc. | Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability |
| LT4209510T (en) | 2008-12-09 | 2024-03-12 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| SG175166A1 (en) * | 2009-04-17 | 2011-11-28 | Biogen Idec Inc | Compositions and methods to treat acute myelogenous leukemia |
| US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| CA2772945A1 (en) | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Screening methods |
| WO2011041393A1 (en) * | 2009-09-29 | 2011-04-07 | Dart Neuroscience Llc | Genes, methods, and compositions related to neurogenesis and its modulation |
| CA2776386C (en) | 2009-10-02 | 2018-02-27 | The Trustees Of Columbia University In The City Of New York | Piscine reovirus immunogenic compositions |
| CN102711826B (en) | 2009-10-22 | 2017-03-29 | 霍夫曼-拉罗奇有限公司 | For the method and composition that the HEPSIN for regulating and controlling macrophage-stimulating albumen is activated |
| CA2812929C (en) * | 2009-11-12 | 2015-02-03 | Texas Tech University | Compositions and methods for treating hyperproliferative disorders |
| CA2781887C (en) | 2009-11-30 | 2018-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| ES2519348T3 (en) | 2010-02-18 | 2014-11-06 | Genentech, Inc. | Neurregulin antagonists and their use in cancer treatment |
| EP2538981B1 (en) | 2010-02-23 | 2017-12-20 | F. Hoffmann-La Roche AG | Compositions and methods for the diagnosis and treatment of tumor |
| MX340683B (en) | 2010-04-16 | 2016-07-21 | Biogen Ma Inc | Anti-vla-4 antibodies. |
| MA34291B1 (en) | 2010-05-03 | 2013-06-01 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR |
| WO2012071436A1 (en) | 2010-11-24 | 2012-05-31 | Genentech, Inc. | Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants |
| GB2503604B (en) | 2011-03-21 | 2020-04-22 | Biodesy Llc | Classification of kinase inhibitors using second harmonic optical techniques |
| US10352936B2 (en) | 2011-04-14 | 2019-07-16 | Apoplogic Pharmaceuticals, Inc. | Use of tumor Fas expression to determine response to anti-cancer therapy |
| DK201370709A (en) | 2011-04-21 | 2013-11-20 | Univ Aberdeen | Protein for use as a medicament |
| KR102292563B1 (en) | 2011-05-31 | 2021-08-24 | 바이오젠 엠에이 인코포레이티드 | Method of assessing risk of pml |
| TR201820873T4 (en) | 2011-08-01 | 2019-01-21 | Hoffmann La Roche | Methods for treating cancer using Pd-1 axis binding antagonists and mech inhibitors. |
| WO2013040433A1 (en) | 2011-09-15 | 2013-03-21 | Genentech, Inc. | Methods of promoting differentiation |
| MX2014004426A (en) | 2011-10-15 | 2014-07-09 | Genentech Inc | Scd1 antagonists for treating cancer. |
| KR20140119114A (en) | 2012-01-18 | 2014-10-08 | 제넨테크, 인크. | Methods of using fgf19 modulators |
| US20130209473A1 (en) | 2012-02-11 | 2013-08-15 | Genentech, Inc. | R-spondin translocations and methods using the same |
| MX2014010953A (en) | 2012-03-16 | 2014-10-13 | Hoffmann La Roche | Methods of treating melanoma with pak1 inhibitors. |
| US9139863B2 (en) | 2012-03-16 | 2015-09-22 | Genentech, Inc. | Engineered conformationally-stabilized proteins |
| CN104254541A (en) | 2012-03-16 | 2014-12-31 | 弗·哈夫曼-拉罗切有限公司 | Engineered conformationally-stabilized proteins |
| JP6302460B2 (en) | 2012-04-25 | 2018-03-28 | バイオデシー， インコーポレイテッド | Methods for detecting allosteric modulators of proteins |
| WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
| SG10201603055WA (en) | 2012-05-31 | 2016-05-30 | Genentech Inc | Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists |
| BR112015017903A2 (en) | 2013-01-28 | 2017-11-21 | Univ Danmarks Tekniske | mycobacterium avium subsp subunit vaccine. single or multistage paratuberculosis |
| MX2015010791A (en) | 2013-02-22 | 2015-11-26 | Hoffmann La Roche | Methods of treating cancer and preventing drug resistance. |
| WO2014138364A2 (en) | 2013-03-06 | 2014-09-12 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| JP2016516046A (en) | 2013-03-14 | 2016-06-02 | ジェネンテック， インコーポレイテッド | Methods for treating cancer and methods for preventing cancer drug resistance |
| KR20150130451A (en) | 2013-03-15 | 2015-11-23 | 제넨테크, 인크. | Methods of treating cancer and preventing cancer drug resistance |
| HUE039291T2 (en) | 2013-03-15 | 2018-12-28 | Hoffmann La Roche | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| BR112015023120A2 (en) | 2013-03-15 | 2017-11-21 | Genentech Inc | method for identifying an individual with a disease or dysfunction, method for predicting the responsiveness of an individual with a disease or dysfunction, method for determining the likelihood that an individual with a disease or dysfunction will exhibit benefit from treatment, method for selecting a therapy, Uses of a pd-11 Axis Binding Antagonist, Assay to Identify an Individual with a Disease, Diagnostic Kit, Method to Evaluate a Treatment Response, and Method to Monitor the Response of a Treated Individual |
| TWI685349B (en) | 2013-07-16 | 2020-02-21 | 建南德克公司 | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| SG11201604875PA (en) | 2013-12-17 | 2016-07-28 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
| WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
| US10955422B2 (en) | 2014-02-27 | 2021-03-23 | Biogen Ma, Inc. | Method of assessing risk of PML |
| RU2020103811A (en) | 2014-05-05 | 2020-02-18 | Регенерон Фармасьютикалз, Инк. | HUMANIZED ANIMALS BY C5 AND C3 |
| EP3146071B1 (en) | 2014-05-23 | 2020-09-02 | F. Hoffmann-La Roche AG | Mit biomarkers and methods using the same |
| WO2015191986A1 (en) | 2014-06-13 | 2015-12-17 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| MX2017000546A (en) | 2014-07-15 | 2017-03-08 | Genentech Inc | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors. |
| EP3188746A4 (en) | 2014-09-05 | 2018-05-02 | The Johns Hopkins University | Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies |
| KR20240024318A (en) | 2014-11-20 | 2024-02-23 | 에프. 호프만-라 로슈 아게 | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| CN107206088A (en) | 2014-12-05 | 2017-09-26 | 豪夫迈·罗氏有限公司 | It is used for the method and composition for the treatment of cancer using the axle antagonists of PD 1 and HPK1 antagonists |
| EP3237906B8 (en) | 2014-12-23 | 2020-10-28 | Bluelight Therapeutics, Inc. | Attachment of proteins to interfaces for use in nonlinear optical detection |
| EP3273974A4 (en) | 2015-03-26 | 2018-11-07 | Women and Infants Hospital of Rhode Island Inc. | Therapy for malignant disease |
| EP4209228A1 (en) | 2015-05-22 | 2023-07-12 | Translational Drug Development, LLC | Benzamide and active compound compositions and methods of use |
| WO2016205681A1 (en) | 2015-06-19 | 2016-12-22 | University Of Rochester | Septin proteins as novel biomarkers for detection and treatment of müllerian cancers |
| CA2989882A1 (en) | 2015-06-26 | 2016-12-29 | The Regents Of The University Of California | Antigenic peptides and uses thereof for diagnosing and treating autism |
| US20180282415A1 (en) | 2015-09-30 | 2018-10-04 | Merck Patent Gmbh | Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer |
| EP3371211A4 (en) | 2015-11-04 | 2019-08-21 | Icahn School of Medicine at Mount Sinai | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment |
| WO2017112956A1 (en) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response |
| JP2019518017A (en) | 2016-02-09 | 2019-06-27 | アレクサンダー・クランツ | Regioselective functionalization of proteins using traceless affinity labeling |
| EP3448881B1 (en) | 2016-04-26 | 2023-06-07 | Icahn School of Medicine at Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
| US11292801B2 (en) | 2016-07-05 | 2022-04-05 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
| JP2020500207A (en) | 2016-09-28 | 2020-01-09 | ブレード・セラピューティクス・インコーポレイテッド | Calpain modulators and their therapeutic use |
| WO2018098401A1 (en) | 2016-11-23 | 2018-05-31 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
| WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
| WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
| SG10202111663PA (en) | 2017-02-27 | 2021-12-30 | Regeneron Pharma | Humanized model of kidney and liver disorders |
| MA49131A (en) | 2017-04-21 | 2020-03-25 | Hoffmann La Roche | USE OF KLK5 ANTAGONISTS FOR THE TREATMENT OF DISEASE |
| EP3615569A1 (en) | 2017-04-25 | 2020-03-04 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
| EP3641752A4 (en) | 2017-06-22 | 2021-03-17 | Moonshot Pharma LLC | Methods for treating cancer with compositions comprising amlexanox and immune modulators |
| WO2019018629A1 (en) | 2017-07-19 | 2019-01-24 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection |
| JP2021502418A (en) | 2017-11-04 | 2021-01-28 | アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド | Compositions and Methods for Modifying Polypeptides |
| WO2019126472A1 (en) | 2017-12-22 | 2019-06-27 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
| CA3141531A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| EP4061414A1 (en) | 2019-11-20 | 2022-09-28 | Intervet International B.V. | A novel vaccine against heamophilus parasuis |
| BR112022008142A2 (en) | 2019-11-20 | 2022-08-23 | Intervet Int Bv | NEW VACCINE AGAINST HEAMOPHILUS PARASUIS |
| WO2021099444A1 (en) | 2019-11-20 | 2021-05-27 | Intervet International B.V. | A novel vaccine against heamophilus parasuis |
| EP4232040A1 (en) | 2020-10-20 | 2023-08-30 | F. Hoffmann-La Roche AG | Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors |
| WO2022118197A1 (en) | 2020-12-02 | 2022-06-09 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
| WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
| WO2022258600A1 (en) | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
| TW202327595A (en) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | Combinations of azalactam compounds for the treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| AU582731B2 (en) * | 1983-01-21 | 1989-04-13 | Milton David Goldenberg | Specific cea-family antigens, antibodies specific thereto and their methods of use |
| NZ207394A (en) * | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| DE3479289D1 (en) * | 1983-11-07 | 1989-09-14 | Wistar Inst | Immune response to tumours and viruses induced by anti-idiotype antibodies |
| DE3586772T2 (en) * | 1984-07-24 | 1993-03-04 | Coselco Mimotopes Pty Ltd | METHOD FOR DETERMINING MIMOTOPES. |
-
1986
- 1986-04-17 NZ NZ215865A patent/NZ215865A/en unknown
- 1986-04-21 CA CA000507185A patent/CA1267084A/en not_active Expired - Lifetime
- 1986-04-22 EP EP86902772A patent/EP0220245B1/en not_active Expired
- 1986-04-22 AT AT86902772T patent/ATE78097T1/en active
- 1986-04-22 JP JP61502598A patent/JPS62502568A/en active Pending
- 1986-04-22 US US07/010,088 patent/US4833092A/en not_active Expired - Lifetime
- 1986-04-22 DE DE8686902772T patent/DE3685930T2/en not_active Expired - Lifetime
- 1986-12-22 NO NO865215A patent/NO168793C/en unknown
- 1986-12-22 DK DK624986A patent/DK165197C/en not_active IP Right Cessation
-
1987
- 1987-09-02 MY MYPI87001514A patent/MY102884A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE3685930D1 (en) | 1992-08-13 |
| JPS62502568A (en) | 1987-10-01 |
| NO168793C (en) | 1992-04-01 |
| NO168793B (en) | 1991-12-23 |
| DE3685930T2 (en) | 1992-12-24 |
| MY102884A (en) | 1993-03-31 |
| ATE78097T1 (en) | 1992-07-15 |
| DK165197B (en) | 1992-10-19 |
| EP0220245A1 (en) | 1987-05-06 |
| EP0220245B1 (en) | 1992-07-08 |
| DK165197C (en) | 1993-03-01 |
| NZ215865A (en) | 1988-10-28 |
| NO865215L (en) | 1986-12-22 |
| DK624986A (en) | 1987-02-22 |
| EP0220245A4 (en) | 1988-01-26 |
| US4833092A (en) | 1989-05-23 |
| DK624986D0 (en) | 1986-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1267084A (en) | Method for determining mimotopes | |
| WO1986006487A1 (en) | Method for determining mimotopes | |
| US5194392A (en) | Method of determining mimotopes | |
| Niman et al. | Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition. | |
| Wilson et al. | Shared amino acid sequences between major histocompatibility complex class II glycoproteins, type XI collagen and Proteus mirabilis in rheumatoid arthritis. | |
| JP4585766B2 (en) | Method for detecting ligands and targets in a mixture | |
| Tribbick | Multipin peptide libraries for antibody and receptor epitope screening and characterization | |
| RU97102113A (en) | CONJUGATE BETWEEN MODIFIED SUPERANTIGEN AND TARGET DIRECTED COMPOUND AND APPLICATION OF THE CONJUGATE | |
| JP5611831B2 (en) | Synthetic immunoreactive peptides with rheumatoid arthritis autoantibodies | |
| Babos et al. | Role of N-or C-terminal biotinylation in autoantibody recognition of citrullin containing filaggrin epitope peptides in rheumatoid arthritis | |
| Sioud et al. | Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto) antigens that may trigger B and T cell responses in autoimmune diseases | |
| Atanassov et al. | New Zealand white rabbits immunized with RNA‐complexed total histones develop an autoimmune‐like response | |
| Adler et al. | T cell epitope analysis with peptides simultaneously synthesized on cellulose membranes: fine mapping of two DQ dependent epitopes | |
| AU592560B2 (en) | Improved method for determining mimotopes | |
| Schein et al. | Synthetic proteins for COVID-19 diagnostics | |
| JPH05271281A (en) | Peptide for production of diagnostic and therapeutic agent of systemic erythematodes | |
| Pinilla et al. | Mapping the detailed specificity of a calcium-dependent monoclonal antibody through the use of soluble positional scanning combinatorial libraries: identification of potent calcium-independent antigens | |
| EP0620231B1 (en) | Human parvovirus B19 epitope-related peptide | |
| Quesniaux et al. | An enzyme immunoassay for the screening of monoclonal antibodies to cyclosporin | |
| US5436127A (en) | Epitope-related peptides of human parvovirus | |
| JP2002058479A (en) | Method for obtaining comformational recognition amino acid sequence | |
| Herfurth et al. | Determination of peptide regions exposed at the surface of the bacterial ribosome with antibodies against synthetic peptides | |
| JP4387945B2 (en) | Anti-idiotype antibody, method for producing the anti-idiotype antibody, and method for preparing an idiotype antibody using the anti-idiotype antibody | |
| WO1996006357A1 (en) | Screen for potential therapeutic compounds | |
| KR100458418B1 (en) | Mimotope Peptides Of Phenolic Glycolipid-I Of Mycobacterium leprae And Kit For Serodiagnosis Of Leprosy Including Said Peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |